سعر كواجولوبان 60 مجم 20 قرص 2026

Coaguloban 60 mg 20 tabs: Edoxaban 60 mg (Marcyrl co.).

• Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation (NVAF); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5–10 days of parenteral anticoagulation (US SAVAYSA). Confirm Egyptian leaflet.Population: AdultsDailyMed (NLM)

• Most common adverse reactions include bleeding and anemia; NVAF trials also reported rash and abnormal liver function tests among others (US label).International label, same formulation · DailyMed (NLM)

• Active pathological bleeding (US SAVAYSA).International label, same formulation · DailyMed (NLM)

• Boxed warnings: premature discontinuation increases risk of ischemic events; spinal/epidural haematoma risk with neuraxial anaesthesia or spinal puncture; reduced efficacy in NVAF patients with CrCL >95 mL/min — do not use SAVAYSA in that group for NVAF (US label).International label, same formulation · DailyMed (NLM)
• Serious and potentially fatal bleeding; not recommended with mechanical heart valves, moderate–severe mitral stenosis, or triple-positive antiphospholipid syndrome (US label).International label, same formulation · DailyMed (NLM)

• Anticoagulants / antiplatelets / NSAIDs / SSRIs/SNRIsMajorAdditive bleeding risk; avoid dual long-term anticoagulation unless indicated; monitor closely.DailyMed (NLM)
• Certain P-gp inhibitorsMajorMay increase edoxaban exposure; US labeling reduces dose for some P-gp inhibitors in VTE treatment.DailyMed (NLM)

• Use in pregnancy only if potential benefit justifies potential risk; anticoagulants increase maternal bleeding risk and may pose fetal risks (US PLLR-style labeling).International label, same formulation · DailyMed (NLM)

• Edoxaban: Selectively inhibits factor Xa, reducing thrombin generation and thrombus formation.